Liraglutide (Saxenda®) in adolescent patients. HTA ID: 24001

Assessment Status Rapid Review Complete
HTA ID 24001
Drug Liraglutide
Brand Saxenda®
Indication Liraglutide is indicated as an adjunct to a healthy nutrition and increased physical activity for weight management in adolescent patients from the age of 12 years and above with: • obesity (body mass index (BMI) corresponding to ≥30 kg/m2 for adults by international cut-off points) and • body weight above 60 kg*
Assessment Process
Rapid review commissioned 05/01/2024
Rapid review completed 09/02/2024
Rapid review outcome A full HTA is not recommended. The NCPE recommends that liraglutide not be considered for reimbursement at the submitted price*.

*The Applicant is requesting reimbursement in a subgroup of the licensed population, namely:

Adolescent patients between the ages 12 to 16 years with a BMI greater than the 99.5th percentile and two or more of the following co-morbidities:

  • Uncontrolled metabolic complications.
  • Biomechanical complications requiring treatment or limited mobility.
  • Shortness of breath.
  • Significant psychosocial complications or concerns.


*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.